和康
和康生 Stock: price and insider trades · Taiwan
TW·Mcap NT$3.3B
和康生: what insiders have been doing
Only a handful of insider records exist for 和康生, the last one from 14 April 2023, too few to describe a trend. These figures are compiled from regulatory filings published by TWSE / TPEx (MOPS). They describe what insiders did and are not a recommendation.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 1,664 of 26,897 companies
77.7
score / 100
Value68
Quality88
FCF yld6.3%
Earn yld8.0%
EV/EBITDA10.1x
ROE20%
Gross mgn69%
Net mgn33%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$37
Analyst consensus
Income statement
RevenueNT$811.6M
Gross profitNT$563.7M69% margin
EBITDANT$337.1M42% margin
Net incomeNT$265.3M34.8% margin
Valuation
PER (trailing)11.4x
P/Book2.2x
Beta0.36
Balance sheet & cash
Market capNT$3.3B
Total debtNT$101.4M
Free Cash FlowNT$207.6M
Debt / Equity7%
Profitability & ownership
ROE20.0%
ROA8.6%
% insiders55.2%
% institutions4.8%
Last declaration on 14 April 2023
Declarations4 total
- 1,359,600 sharesShareTWSETWMOPS:1783:112/04/14:林詠翔:1dx0ssy
- 3,068,000 sharesShareTWSETWMOPS:1783:110/04/21:環宇投資股份有公司:0bcx1af
- 764,767 sharesShareTWSETWMOPS:1783:110/04/21:環宇財務顧問股份有限公司:02nf3hv
- 75,000 sharesShareTWSETWMOPS:1783:104/07/30:侯福仁:1sbnzhh
4 of 4 declarations
About 和康生
和康生 is a company listed on the XTAI market, specializing in the healthcare sector.